PT  - JOURNAL ARTICLE
AU  - Looker, H C
AU  - Nyangoma, S O
AU  - Cromie, D T
AU  - Olson, J A
AU  - Leese, G P
AU  - Black, M W
AU  - Doig, J
AU  - Lee, N
AU  - Lindsay, R S
AU  - McKnight, J A
AU  - Morris, A D
AU  - Pearson, D W M
AU  - Philip, S
AU  - Wild, S H
AU  - Colhoun, H M
AU - on behalf of the Scottish Diabetes Research Network Epidemiology Group and the Scottish Diabetic Retinopathy Collaborative
TI  - Rates of referable eye disease in the Scottish National Diabetic Retinopathy Screening Programme
AID  - 10.1136/bjophthalmol-2013-303948
DP  - 2014 Jun 01
TA  - British Journal of Ophthalmology
PG  - 790--795
VI  - 98
IP  - 6
4099  - http://bjo.bmj.com/content/98/6/790.short
4100  - http://bjo.bmj.com/content/98/6/790.full
SO  - Br J Ophthalmol2014 Jun 01; 98
AB  - Aims Diabetic retinopathy screening aims to detect people at risk of visual loss due to proliferative diabetic retinopathy, but also refers cases of suspected macular oedema (maculopathy). At the introduction of screening, ophthalmology was concerned that referral rates would be unmanageable. We report yield of referable disease by referral reason for the first 5 years of the programme. Methods We extracted screening results from a nationwide clinical diabetes database to calculate annual referral rates to ophthalmic clinics. We used logistic regression to examine associations between clinical measures and referable disease. Results 182 397 people underwent ≥1successful retinal screening between 2006 and 2010. The yield of referable eye disease was highest in the first 2 years of screening (7.0% and 6.0%) before stabilising at ∼4.3%. The majority of referrals are due to maculopathy with 73% of referrals in 2010 based on a finding of maculopathy. Conclusions The commonest cause for referral is for suspected macular oedema (maculopathy). Referral rates for retinopathy have stabilised, as predicted, at relatively low rates. However, ophthalmology workload continues to rise as new treatment options (ie, monthly intraocular injections) have unexpectedly increased the impact on ophthalmology. A review of the screening referral path for maculopathy may be timely.